U.S. Electric Utilities Stock News

NYSE:JEF
NYSE:JEFCapital Markets

Is Jefferies Financial Group (JEF) Fully Priced After Its Recent Share Price Strength

Wondering if Jefferies Financial Group at around US$52 per share offers good value right now, or if most of the opportunity is already on the table. The stock is down about 1.4% over the past week, up 11.5% over the past month, roughly flat with a 2.0% gain over the last year, and has returned 85.6% over three years and 97.7% over five years. These moves have come alongside ongoing interest in capital markets and financial services companies, with Jefferies often in focus when investors...
NasdaqGM:IVVD
NasdaqGM:IVVDBiotechs

Invivyd (IVVD) Q1 Loss Of US$41.4 Million Reinforces Bearish Unprofitability Narrative

Invivyd (IVVD) has released its Q1 2026 numbers with revenue of about US$13.7 million and a basic EPS loss of US$0.13, alongside a trailing 12 month net loss of US$77.6 million. The company has seen revenue move from US$25.4 million in Q4 2024 on a trailing 12 month basis to US$55.9 million in the latest trailing period, while trailing basic EPS has shifted from a loss of US$1.43 to a loss of US$0.35. Investors are therefore looking at a business where top line momentum is meeting still heavy...
NasdaqGS:TYRA
NasdaqGS:TYRABiotechs

Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?

Tyra Biosciences, Inc. recently reported first-quarter 2026 results showing a wider net loss of US$39.31 million and basic loss per share of US$0.64, while highlighting progress across three Phase 2 trials for its lead candidate dabogratinib and a cash balance of US$383.5 million supporting operations into the second half of 2028. An interesting angle for investors is how Tyra’s “dabogratinib 3×3” plan concentrates resources on three FGFR3-driven indications, potentially shaping its future...
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements

Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that could influence how investors view the stock. See our latest analysis for Humacyte. The share price has been volatile, with a 1 month share price return of 26.36% but a 1 year total shareholder return that is down 58.48%. This reflects shifting sentiment as investors weigh fresh capital raises,...
OTCPK:RLEA
OTCPK:RLEAAuto Components

Rubber Leaf (OTCPK:RLEA) Turns Q1 EPS Positive Yet Ongoing Losses Challenge Bullish Narratives

Rubber Leaf (OTCPK:RLEA) opened 2026 with Q1 revenue of about US$3.3 million and basic EPS of roughly US$0.01, with the stock trading around US$4.50. Over recent periods, the company has seen quarterly revenue range from US$0 to about US$3.3 million while basic EPS has moved between a loss of roughly US$0.01 and a gain of just under US$0.01. This gives investors a clear view of how sensitive margins have been to shifts in activity levels. See our full analysis for Rubber Leaf. With the...
NasdaqGM:GUTS
NasdaqGM:GUTSMedical Equipment

Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, its Smart GLP-1 gene therapy candidate for type 2 diabetes. An important detail for investors is that this regulatory clearance makes Fractyl a dual clinical-stage company, advancing both its Revita procedure for post‑GLP‑1 weight maintenance and its Rejuva gene therapy platform...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Progress Software Award Spotlights Agentic RAG And Undervalued AI Potential

Progress Software (NasdaqGS:PRGS) has received a 2026 Artificial Intelligence Excellence Award for its Agentic RAG platform. The award recognizes the platform in the Retrieval Augmented Generation (RAG) category for its role in AI driven data solutions. Agentic RAG focuses on converting unstructured data into governed intelligence for enterprise use. For you as an investor, this award draws attention to how Progress Software is positioning itself around operational AI rather than only...